title: Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism.
authors.affiliation: Department of Clinical and Biological Sciences; Department of Medical Oncology and.
authors.forename: E
authors.initials: E
authors.lastname: Bellini
authors.affiliation: Department of Clinical and Biological Sciences; Department of Internal Medicine, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Pia
authors.affiliation: Department of Clinical and Biological Sciences; Department of Medical Oncology and.
authors.forename: M P
authors.initials: MP
authors.lastname: Brizzi
authors.affiliation: Department of Medical Oncology and.
authors.forename: M
authors.initials: M
authors.lastname: Tampellini
authors.affiliation: Department of Clinical and Biological Sciences; Department of Medical Oncology and.
authors.forename: M
authors.initials: M
authors.lastname: Torta
authors.affiliation: Department of Clinical and Biological Sciences; Department of Internal Medicine, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Terzolo
authors.affiliation: Department of Clinical and Biological Sciences; Department of Medical Oncology and.
authors.forename: L
authors.initials: L
authors.lastname: Dogliotti
authors.affiliation: Department of Medical Oncology and. Electronic address: alfredo.berruti@gmail.com.
authors.forename: A
authors.initials: A
authors.lastname: Berruti
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000009:adverse effects* / Q000627:therapeutic use; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000378:metabolism*; D006801:Humans; D017674:Hypophosphatemia / Q000139:chemically induced* / Q000378:metabolism*; D007680:Kidney Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; C000717427:FGF23 protein, human; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D005346:Fibroblast Growth Factors; D000089703:Fibroblast Growth Factor-23; D000077157:Sorafenib